Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2010 1
2011 2
2012 1
2013 1
2015 1
2016 1
2020 1
2022 1
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
ET-743: a novel agent with activity in soft tissue sarcomas.
Fayette J, Coquard IR, Alberti L, Ranchère D, Boyle H, Blay JY. Fayette J, et al. Among authors: coquard ir. Oncologist. 2005 Nov-Dec;10(10):827-32. doi: 10.1634/theoncologist.10-10-827. Oncologist. 2005. PMID: 16314293 Free article. Review.
ET-743: a novel agent with activity in soft-tissue sarcomas.
Fayette J, Coquard IR, Alberti L, Boyle H, Méeus P, Decouvelaere AV, Thiesse P, Sunyach MP, Ranchère D, Blay JY. Fayette J, et al. Among authors: coquard ir. Curr Opin Oncol. 2006 Jul;18(4):347-53. doi: 10.1097/01.cco.0000228740.70379.3f. Curr Opin Oncol. 2006. PMID: 16721129 Review.
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
Colomba E, Alexandre J, Le Teuff G, Genestie C, Coupez D, Coquard IR, Brachet PE, de Percin S, Sajous C, Fabbro M, Delanoy N, Joly F, Frenel JS, Pautier P, Leary A. Colomba E, et al. Among authors: coquard ir. Gynecol Oncol. 2023 Feb;169:78-84. doi: 10.1016/j.ygyno.2022.11.029. Epub 2022 Dec 13. Gynecol Oncol. 2023. PMID: 36521352
The burden of rare cancers in Europe.
Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group. Gatta G, et al. Adv Exp Med Biol. 2010;686:285-303. doi: 10.1007/978-90-481-9485-8_17. Adv Exp Med Biol. 2010. PMID: 20824452 Review.
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, Pautier P, Angeles MA, Delanoy N, Lefeuvre-Plesse C, Cancel M, Treilleux I, Augereau P, Lavoue V, Kalbacher E, Berton Rigaud D, Selle F, Nadeau C, Gantzer J, Joly F, Guillemet C, Pomel C, Favier L, Abdeddaim C, Venat-Bouvet L, Provansal M, Fabbro M, Kaminsky MC, Lortholary A, Lecuru F, Coquard IR, de La Motte Rouge T. Derquin F, et al. Among authors: coquard ir. Gynecol Oncol. 2020 Sep;158(3):666-672. doi: 10.1016/j.ygyno.2020.06.491. Epub 2020 Jul 3. Gynecol Oncol. 2020. PMID: 32624235
Rare cancers are not so rare: the rare cancer burden in Europe.
Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Gatta G, et al. Eur J Cancer. 2011 Nov;47(17):2493-511. doi: 10.1016/j.ejca.2011.08.008. Epub 2011 Oct 25. Eur J Cancer. 2011. PMID: 22033323
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO). Despierre E, et al. Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Target Oncol. 2015. PMID: 26004768 Free PMC article. Clinical Trial.